Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
25
11
2020
accepted:
25
03
2021
revised:
09
03
2021
pubmed:
13
5
2021
medline:
14
10
2021
entrez:
12
5
2021
Statut:
ppublish
Résumé
The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30-46%) at 2 years and 25% (17-32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24-46%); Others 9% (0-17%), p < 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50% (33-67%); Other 22% (8-36%), p = 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21-40%) vs. 10% (1-20%), P = 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24-0.67), p < 0.001). In the graft failure group, OS was 41% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.
Identifiants
pubmed: 33976382
doi: 10.1038/s41409-021-01286-x
pii: 10.1038/s41409-021-01286-x
pmc: PMC8486670
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2367-2381Informations de copyright
© 2021. The Author(s).
Références
Craddock C, Hoelzer D, Komanduri KV. Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia. Bone Marrow Transpl. 2019;54:6–16. https://doi.org/10.1038/s41409-018-0203-8 . e-pub ahead of print 2018/06/02
doi: 10.1038/s41409-018-0203-8
Sureda A, Dreger P, Bishop MR, Kroger N, Porter DL. Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies. Bone Marrow Transpl. 2019;54:17–25. https://doi.org/10.1038/s41409-018-0214-5 . e-pub ahead of print 2018/05/26
doi: 10.1038/s41409-018-0214-5
Chen YB, McCarthy PL, Hahn T, Holstein SA, Ueda M, Kroger N, et al. Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents. Bone Marrow Transpl. 2019;54:497–507. https://doi.org/10.1038/s41409-018-0269-3 . e-pub ahead of print 2018/07/25
doi: 10.1038/s41409-018-0269-3
Falkenburg F, Ruggiero E, Bonini C, Porter D, Miller J, Malard F, et al. Prevention and treatment of relapse after stem cell transplantation by cellular therapies. Bone Marrow Transpl. 2019;54:26–34. https://doi.org/10.1038/s41409-018-0227-0 . e-pub ahead of print 2018/05/26
doi: 10.1038/s41409-018-0227-0
Shaw BE, Mufti GJ, Mackinnon S, Cavenagh JD, Pearce RM, Towlson KE, et al. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transpl. 2008;42:783–9. https://doi.org/10.1038/bmt.2008.255 . e-pub ahead of print 2008/08/30
doi: 10.1038/bmt.2008.255
Vrhovac R, Labopin M, Ciceri F, Finke J, Holler E, Tischer J, et al. Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes. Bone Marrow Transpl. 2016;51(2):186–93. https://doi.org/10.1038/bmt.2015.221 . e-pub ahead of print 2015/10/06
doi: 10.1038/bmt.2015.221
Weisdorf D. The role of second transplants for leukemia. Best Pr Res Clin Haematol. 2016;29:359–64. https://doi.org/10.1016/j.beha.2016.10.011 . e-pub ahead of print 2016/11/29
doi: 10.1016/j.beha.2016.10.011
Aljasem HA, Messner HA, Lipton JH, Kim DDH, Viswabandya A, Thyagu S, et al. Outcome following second allogeneic hematopoietic cell transplantation: a single-center experience. Eur J Haematol. 2018;100:308–14. https://doi.org/10.1111/ejh.13015 . e-pub ahead of print 2017/12/15
doi: 10.1111/ejh.13015
pubmed: 29240253
Moukalled NM, Kharfan-Dabaja MA. What is the role of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia? Bone Marrow Transpl. 2019. https://doi.org/10.1038/s41409-019-0584-3 . e-pub ahead of print 2019/06/05
doi: 10.1038/s41409-019-0584-3
Shimomura Y, Hara M, Tachibana T, Ohashi K, Sakura T, Fukuda T, et al. Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome. Br J Haematol. 2019;186:86–90. https://doi.org/10.1111/bjh.15898 . e-pub ahead of print 2019/04/04
doi: 10.1111/bjh.15898
pubmed: 30941758
Radich JP, Sanders JE, Buckner CD, Martin PJ, Petersen FB, Bensinger W, et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol. 1993;11:304–13. https://doi.org/10.1200/JCO.1993.11.2.304 . e-pub ahead of print 1993/02/01
doi: 10.1200/JCO.1993.11.2.304
pubmed: 8426208
Michallet M, Tanguy ML, Socie G, Thiebaut A, Belhabri A, Milpied N, et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle (SFGM). Br J Haematol. 2000;108:400–7. https://doi.org/10.1046/j.1365-2141.2000.01851.x . e-pub ahead of print 2000/02/26
doi: 10.1046/j.1365-2141.2000.01851.x
pubmed: 10691873
Ruutu T, de Wreede LC, van Biezen A, Brand R, Mohty M, Dreger P, et al. Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transpl. 2015;50:1542–50. https://doi.org/10.1038/bmt.2015.186 . e-pub ahead of print 2015/09/15
doi: 10.1038/bmt.2015.186
Ferra C, Sanz J, Diaz-Perez MA, Morgades M, Gayoso J, Cabrera JR, et al. Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. Leuk Lymphoma. 2015;56:656–62. https://doi.org/10.3109/10428194.2014.930849 . e-pub ahead of print 2014/06/11
doi: 10.3109/10428194.2014.930849
pubmed: 24913510
Lund TC, Liegel J, Bejanyan N, Orchard PJ, Cao Q, Tolar J, et al. Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure. Am J Hematol. 2015;90:892–6. https://doi.org/10.1002/ajh.24111 . e-pub ahead of print 2015/07/08
doi: 10.1002/ajh.24111
pubmed: 26149534
pmcid: 4579006
Schriber J, Agovi MA, Ho V, Ballen KK, Bacigalupo A, Lazarus HM, et al. Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transpl. 2010;16:1099–106. https://doi.org/10.1016/j.bbmt.2010.02.013 . e-pub ahead of print 2010/02/23
doi: 10.1016/j.bbmt.2010.02.013
Novak P, Klyuchnikov E, von Pein UM, Gullstorf M, Christopeit M, Ayuk F, et al. Second allogeneic stem cell transplantation for relapse after allografting in multiple myeloma using CD 34+ selected donor cells without immunosuppression. Bone Marrow Transpl. 2020;55:1817–20. https://doi.org/10.1038/s41409-020-0912-7 . e-pub ahead of print 2020/05/01
doi: 10.1038/s41409-020-0912-7
Kishi K, Takahashi S, Gondo H, Shiobara S, Kanamaru A, Kato S, et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes. Bone Marrow Transpl. 1997;19:461–6. https://doi.org/10.1038/sj.bmt.1700680 . e-pub ahead of print 1997/03/01
doi: 10.1038/sj.bmt.1700680
Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ, et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transpl. 2004;34:721–7. https://doi.org/10.1038/sj.bmt.1704645 . e-pub ahead of print 2004/08/24
doi: 10.1038/sj.bmt.1704645
Hayden PJ, Iacobelli S, Perez-Simon JA, van Biezen A, Minnema M, Niittyvuopio R, et al. Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP. Eur J Haematol. 2019. https://doi.org/10.1111/ejh.13352 . e-pub ahead of print 2019/11/19
doi: 10.1111/ejh.13352
pubmed: 31737951
Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, Shah N, et al. Comparison of outcomes of allogeneic hematopoietic cell transplantation for multiple myeloma using three different conditioning regimens. Biol Blood Marrow Transpl. 2019;25:1039–44. https://doi.org/10.1016/j.bbmt.2019.01.009 . e-pub ahead of print 2019/01/15
doi: 10.1016/j.bbmt.2019.01.009
Schneidawind C, Duerr-Stoerzer S, Faul C, Kanz L, Weisel K, Bethge W et al. Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation. Clin Transplant 2017; 31. https://doi.org/10.1111/ctr.12994 . e-pub ahead of print 2017/05/05
Giaccone L, Evangelista A, Patriarca F, Sorasio R, Pini M, Carnevale-Schianca F, et al. Impact of new drugs on the long-term follow-up of upfront tandem autograft-allograft in multiple myeloma. Biol Blood Marrow Transpl. 2018;24:189–93. https://doi.org/10.1016/j.bbmt.2017.09.017 . e-pub ahead of print 2017/10/11
doi: 10.1016/j.bbmt.2017.09.017
Htut M, D’Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, et al. Autologous/allogeneic hematopoietic cell transplantation versus tandem autologous transplantation for multiple myeloma: comparison of long-term postrelapse survival. Biol Blood Marrow Transpl. 2018;24:478–85. https://doi.org/10.1016/j.bbmt.2017.10.024 . e-pub ahead of print 2017/10/29
doi: 10.1016/j.bbmt.2017.10.024